{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:10:37Z","timestamp":1791821437184,"version":"4.3.4"},"reference-count":133,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jacc.2023.10.038","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T13:57:03Z","timestamp":1705327023000},"page":"444-465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["When Direct Oral Anticoagulants Should Not Be Standard Treatment"],"prefix":"10.1016","volume":"83","author":[{"given":"Antoine","family":"Bejjani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candrika D.","family":"Khairani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Assi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-5276","authenticated-orcid":false,"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-0513","authenticated-orcid":false,"given":"Parham","family":"Sadeghipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azita H.","family":"Talasaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fanikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Siegal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey D.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlyn A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Kleindorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Monreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Middeldorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.V.","family":"Elkind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Cushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jacc.2023.10.038_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197583","article-title":"Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis","volume":"13","author":"Makam","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jacc.2023.10.038_bib2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"9921","key":"10.1016\/j.jacc.2023.10.038_bib3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jacc.2023.10.038_bib4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jacc.2023.10.038_bib5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jacc.2023.10.038_bib6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.jacc.2023.10.038_bib7","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jacc.2023.10.038_bib8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jacc.2023.10.038_bib9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.jacc.2023.10.038_bib10","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Investigators","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jacc.2023.10.038_bib11","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.jacc.2023.10.038_bib12","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.jacc.2023.10.038_bib13","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Investigators","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jacc.2023.10.038_bib14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.jacc.2023.10.038_bib15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jacc.2023.10.038_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.jacc.2023.10.038_bib17","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.jacc.2023.10.038_bib18","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in Peripheral Artery Disease after Revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jacc.2023.10.038_bib19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1712746","article-title":"Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty","volume":"378","author":"Anderson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9717","key":"10.1016\/j.jacc.2023.10.038_bib20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jacc.2023.10.038_bib21","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.thromres.2014.09.011","article-title":"Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial","volume":"134","author":"Fuji","year":"2014","journal-title":"Thromb Res"},{"issue":"11","key":"10.1016\/j.jacc.2023.10.038_bib22","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"26","key":"10.1016\/j.jacc.2023.10.038_bib23","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9591","key":"10.1016\/j.jacc.2023.10.038_bib24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jacc.2023.10.038_bib25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1160\/TH10-10-0679","article-title":"Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II\u2217). A randomised, double-blind, non-inferiority trial","volume":"105","author":"Eriksson","year":"2011","journal-title":"Thromb Haemost"},{"issue":"26","key":"10.1016\/j.jacc.2023.10.038_bib26","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9632","key":"10.1016\/j.jacc.2023.10.038_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.jacc.2023.10.038_bib28","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9676","key":"10.1016\/j.jacc.2023.10.038_bib29","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacc.2023.10.038_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Committee","year":"2009","journal-title":"J\u00a0Arthroplasty"},{"issue":"1","key":"10.1016\/j.jacc.2023.10.038_bib31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jacc.2023.10.038_bib32","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper","volume":"59","author":"De Caterina","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.jacc.2023.10.038_bib33","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jacc.2023.10.038_bib34","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jacc.2023.10.038_bib35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"direct oral anticoagulants vs vitamin-K antagonists in thrombotic antiphospholipid syndrome: meta-analysis of randomized controlled trials","volume":"81","author":"Khairani","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacc.2023.10.038_bib36","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.jacc.2023.10.038_bib37","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jacc.2023.10.038_bib38","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin k antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jacc.2023.10.038_bib39","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jacc.2023.10.038_bib40","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.jacc.2023.10.038_bib41","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jacc.2023.10.038_bib42","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an on-x mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evidence"},{"issue":"23","key":"10.1016\/j.jacc.2023.10.038_bib43","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jacc.2023.10.038_bib44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A\u00a0controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jacc.2023.10.038_bib45","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial","volume":"146","author":"Park","year":"2022","journal-title":"Circulation"},{"issue":"29","key":"10.1016\/j.jacc.2023.10.038_bib46","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.jacc.2023.10.038_bib47","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"Hart","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.jacc.2023.10.038_bib48","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source","volume":"380","author":"Diener","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl_1","key":"10.1016\/j.jacc.2023.10.038_bib49","article-title":"Apixaban for treatment of embolic stroke of undetermined source (ATTICUS) randomized trial \u2013 update of patient characteristics and study timeline after interim analysis","volume":"42","author":"Poli","year":"2021","journal-title":"Eur Heart J"},{"issue":"Suppl_1","key":"10.1016\/j.jacc.2023.10.038_bib50","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1161\/str.54.suppl_1.31","article-title":"Abstract 31: The ATTICUS randomized controlled trial - subgroup analyses","volume":"54","author":"Poli","year":"2023","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.jacc.2023.10.038_bib51","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1160\/TH13-12-1047","article-title":"Only high levels of dabigatran attenuate catheter thrombosis in\u00a0vitro and in rabbits","volume":"112","author":"Yau","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2023.10.038_bib52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2022.05.014","article-title":"Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial","volume":"216","author":"Brandt","year":"2022","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.jacc.2023.10.038_bib53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtha.2022.10.020","article-title":"Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in\u00a0vitro","volume":"21","author":"Guan","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"10.1016\/j.jacc.2023.10.038_bib54","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jamaneurol.2019.2764","article-title":"Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial","volume":"76","author":"Ferro","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacc.2023.10.038_bib55","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacc.2023.10.038_bib56","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.jacc.2023.10.038_bib57","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A\u00a0randomized controlled trial comparing apixaban with the vitamin k antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 Study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacc.2023.10.038_bib58","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1055\/s-0039-1697682","article-title":"Venous thromboembolism in patients with liver cirrhosis: findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) Registry","volume":"45","author":"Bikdeli","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"19","key":"10.1016\/j.jacc.2023.10.038_bib59","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","article-title":"Oral anticoagulation in patients with liver disease","volume":"71","author":"Qamar","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2023.10.038_bib60","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.13353","article-title":"Examining the transplacental passage of apixaban using the dually perfused human placenta","volume":"14","author":"Bapat","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"10.1016\/j.jacc.2023.10.038_bib61","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/AOG.0000000000000277","article-title":"Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta","volume":"123","author":"Bapat","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.jacc.2023.10.038_bib62","doi-asserted-by":"crossref","first-page":"e884","DOI":"10.1016\/S2352-3026(20)30327-6","article-title":"Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study","volume":"7","author":"Beyer-Westendorf","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.jacc.2023.10.038_bib63","doi-asserted-by":"crossref","first-page":"710e1","DOI":"10.1016\/j.ajog.2015.06.065","article-title":"Rivaroxaban transfer across the dually perfused isolated human placental cotyledon","volume":"213","author":"Bapat","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.jacc.2023.10.038_bib64","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacc.2023.10.038_bib65","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.jacc.2023.10.038_bib66","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10206","key":"10.1016\/j.jacc.2023.10.038_bib67","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.jacc.2023.10.038_bib68","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9683","key":"10.1016\/j.jacc.2023.10.038_bib69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacc.2023.10.038_bib70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jacc.2023.10.038_bib71","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacc.2023.10.038_bib72","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jacc.2023.10.038_bib73","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1160\/TH-17-10-0709","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1016\/j.jacc.2023.10.038_bib74","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jacc.2016.12.038","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease","volume":"69","author":"Renda","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.jacc.2023.10.038_bib75","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimaraes","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.jacc.2023.10.038_bib76","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1016\/j.jacc.2019.04.039","article-title":"Valvular atrial fibrillation: a confusing and obsolete definition","volume":"73","author":"Giancaterino","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacc.2023.10.038_bib77","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jacc.2023.10.038_bib78","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.jacc.2023.10.038_bib79","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.jacc.2023.10.038_bib80","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"17","key":"10.1016\/j.jacc.2023.10.038_bib81","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jacc.2023.10.038_bib82","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacc.2023.10.038_bib83","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.recesp.2021.10.016","volume":"75","author":"Visseren","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"3","key":"10.1016\/j.jacc.2023.10.038_bib84","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40256-020-00449-3","article-title":"Rivaroxaban versus warfarin in patients with mechanical heart valves: open-label, proof-of-concept trial-the RIWA study","volume":"21","author":"Duraes","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"10.1016\/j.jacc.2023.10.038_bib85","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacc.2023.10.038_bib86","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood. Mar 1"},{"issue":"10","key":"10.1016\/j.jacc.2023.10.038_bib87","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jacc.2023.10.038_bib88","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source with permission from the case for a new clinical construct","volume":"13","author":"Hart","year":"2014","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.jacc.2023.10.038_bib89","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/1747493018799981","article-title":"The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods","volume":"14","author":"Kamel","year":"2019","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jacc.2023.10.038_bib90","author":"Davenport"},{"issue":"7","key":"10.1016\/j.jacc.2023.10.038_bib91","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.jacc.2023.10.038_bib92","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003709","article-title":"Increased thromboembolic events with dabigatran compared with vitamin k antagonism in left ventricular assist device patients: a randomized controlled pilot trial","volume":"10","author":"Andreas","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2023.10.038_bib93","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.healun.2012.09.013","article-title":"The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary","volume":"32","author":"Feldman","year":"2013","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.jacc.2023.10.038_bib94","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/ejhf.2327","article-title":"Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist health care provider: executive summary","volume":"23","author":"Ben Gal","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"10.1016\/j.jacc.2023.10.038_bib95","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease","volume":"379","author":"Zannad","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jacc.2023.10.038_bib96","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jcin.2022.01.285","article-title":"Prophylactic rivaroxaban therapy for left ventricular thrombus after anterior st-segment elevation myocardial infarction","volume":"15","author":"Zhang","year":"2022","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"issue":"15","key":"10.1016\/j.jacc.2023.10.038_bib97","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association","volume":"146","author":"Levine","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacc.2023.10.038_bib98","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2021.01.049","article-title":"Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT Trial)","volume":"77","author":"Abdelnabi","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2023.10.038_bib99","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/JCPC.JCPC_41_20","article-title":"Apixaban versus warfarin in patients with left ventricular thrombus: a pilot prospective randomized outcome blinded study investigating size reduction or resolution of left ventricular thrombus","volume":"9","author":"Isa W","year":"2020","journal-title":"J\u00a0Clin Prev Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2023.10.038_bib100","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ehjcvp\/pvab057","article-title":"Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trialdouble dagger","volume":"8","author":"Alcalai","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2023.10.038_bib101","article-title":"Are direct oral anticoagulants preferable to warfarin for the treatment of left ventricular thrombi? A Bayesian meta-analysis of randomized controlled trials","volume":"12","author":"Sayed","year":"2021","journal-title":"American Heart Journal Plus: Cardiology Research and Practice"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2023.10.038_bib102","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood-2022-159135","article-title":"A\u00a0prospective study of apixaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients: catheter 3","volume":"140","author":"Kovacs","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jacc.2023.10.038_bib103","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jacc.2023.10.038_bib104","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12517","article-title":"Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): a two-center open-label pilot randomized controlled trial","volume":"5","author":"Ikesaka","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"12","key":"10.1016\/j.jacc.2023.10.038_bib105","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200104","article-title":"Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis","volume":"1","author":"Plessier","year":"2022","journal-title":"NEJM Evidence"},{"issue":"7","key":"10.1016\/j.jacc.2023.10.038_bib106","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jth.14836","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation","volume":"18","author":"Di Nisio","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.jacc.2023.10.038_bib107","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/2396987317719364","article-title":"European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology","volume":"2","author":"Ferro","year":"2017","journal-title":"Eur Stroke J"},{"issue":"4","key":"10.1016\/j.jacc.2023.10.038_bib108","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/STR.0b013e31820a8364","article-title":"Diagnosis and management of cerebral venous thrombosis: a statement for health care professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Saposnik","year":"2011","journal-title":"Stroke"},{"issue":"10","key":"10.1016\/j.jacc.2023.10.038_bib109","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/europace\/euab218","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: comment-Authors' reply","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"issue":"7","key":"10.1016\/j.jacc.2023.10.038_bib110","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2022.1292","article-title":"Efficacy and safety considerations with dose-reduced direct oral anticoagulants: a review","volume":"7","author":"Bikdeli","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"17","key":"10.1016\/j.jacc.2023.10.038_bib111","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","article-title":"Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week","volume":"74","author":"Kumar","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2023.10.038_bib112","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1002\/ajh.25652","article-title":"Investigation of dabigatran secretion into breast milk: Implications for oral thromboprophylaxis in postpartum women","volume":"95","author":"Ayuk","year":"2020","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.jacc.2023.10.038_bib113","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2020006231","article-title":"Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?","volume":"136","author":"Zhao","year":"2020","journal-title":"Blood"},{"issue":"10285","key":"10.1016\/j.jacc.2023.10.038_bib114","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(21)00682-6","article-title":"Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss","volume":"397","author":"Quenby","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacc.2023.10.038_bib115","first-page":"1","article-title":"Centers for Disease C, Prevention. Update on overall prevalence of major birth defects--Atlanta, Georgia, 1978-2005","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.jacc.2023.10.038_bib116","doi-asserted-by":"crossref","first-page":"30","DOI":"10.21859\/ijcp-020201","article-title":"Thrombotic and Thromboembolic Complications in Patients With Adult Congenital Heart Disease","volume":"2","author":"Bikdeli","year":"2017","journal-title":"International Journal of Cardiovascular Practice"},{"issue":"6","key":"10.1016\/j.jacc.2023.10.038_bib117","article-title":"Non-vitamin K oral anticoagulants in adults with congenital heart disease: a systematic review","volume":"9","author":"Stalikas","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jacc.2023.10.038_bib118","article-title":"Head-to-head comparison between direct oral anticoagulants and vitamin K antagonists for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis","author":"Burmeister","year":"2022","journal-title":"Curr Probl Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2023.10.038_bib119","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061225","article-title":"Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial-KABUKI trial","volume":"12","author":"Hosokawa","year":"2022","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.jacc.2023.10.038_bib120","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"10.1016\/j.jacc.2023.10.038_bib121","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/ajh.26194","article-title":"Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia","volume":"96","author":"Nilius","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jacc.2023.10.038_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100283","article-title":"Heparin induced thrombocytopenia: An illustrated review","volume":"7","author":"May","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"13","key":"10.1016\/j.jacc.2023.10.038_bib123","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2023.10.038_bib124","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"10.1016\/j.jacc.2023.10.038_bib125","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.jacc.2023.10.038_bib126","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/ATVBAHA.117.309223","article-title":"Anticoagulation for mechanical heart valves: will oral factor Xa inhibitors be effective?","volume":"37","author":"Chan","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.jacc.2023.10.038_bib127","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.athoracsur.2019.10.091","article-title":"Rivaroxaban and dabigatran for suppression of mechanical heart valve-induced thrombin generation","volume":"110","author":"Jaffer","year":"2020","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.jacc.2023.10.038_bib128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00281-022-00916-w","article-title":"Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome","volume":"44","author":"Knight","year":"2022","journal-title":"Semin Immunopathol"},{"issue":"8","key":"10.1016\/j.jacc.2023.10.038_bib129","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week","volume":"81","author":"Harrington","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jacc.2023.10.038_bib130","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/CIRCULATIONAHA.122.061132","article-title":"What is the future of factor XI inhibitors?","volume":"146","author":"Weitz","year":"2022","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.jacc.2023.10.038_bib131","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.jacc.2023.10.038_bib132","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacc.2023.10.038_bib133","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/jth.12527","article-title":"Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH","volume":"12","author":"Zwicker","year":"2014","journal-title":"J\u00a0Thromb Haemost"}],"updated-by":[{"DOI":"10.1016\/j.jacc.2024.02.032","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000}}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972308052X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510972308052X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T21:13:44Z","timestamp":1737580424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510972308052X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":133,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S073510972308052X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.10.038","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When Direct Oral Anticoagulants Should Not Be Standard Treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.10.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}